ISSN: 1080-6059
To the Editor: The article by Harris et al., published in the August 2007 issue of Emerging Infectious Diseases, examined the risk factors for selecting extended-spectrum β-lactamase–producing Enterobacteriaceae in intensive-care patients and found that exposure to piperacillin/tazobactam and vancomycin were independent risk factors (1). Although antimicrobial drug use has been historically linked to antibiotic resistance in bacteria, we should not miss the perspective that such a risk factor mostly favors the cross-transmission of preexisting antibiotic-resistant bacteria, taking into account the disruption of the endogenous microflora, rather than the selection of "de novo" resistant mutants (2). This supposition is supported by many articles that have found genetic similarity between antibiotic-resistant microorganisms that occur in hospitalized patients, as well as by the fact that most of these pathogens exhibit cross-resistance with different classes of drugs, which should be extremely rare on a mutation basis.
This hypothesis is also supported by the evidence that healthcare workers frequently do not obey simple infection control precautions such as practicing hand hygiene between contact with different patients (3–6). That is likely why Larson et al., in a multicenter study in the United States, recently found no relationship between antimicrobial drug control policies and level of antibiotic resistance in bacteria, but did find an association between lower levels of antibiotic resistance in Staphylococcus aureus and enterococci and high compliance with hand hygiene (7).
Therefore, perhaps we should start looking for risk factors for being colonized or infected by any antimicrobial drug–resistant bacterium, including in our analysis some infection control measures adopted commonly during outbreak investigations, such as exposure to doctor A or nurse B, proximity to a known colonized patient, understaffing during the period of the study, and so forth. If we do so, we will likely find that antimicrobial drug use is not a completely independent risk factor for the mentioned outcome, but a risk factor closely related to the availability of the antibiotic-resistant microorganism in the local environment or on our own hands.
Fernando Bellissimo-Rodrigues*
*Hospital das ClĂnicas da Faculdade de Medicina de Ribeirão Preto, São Paulo, Brazil
Suggested citation for this article:
Bellissimo-Rodrigues F. Antimicrobial
drug use and antibiotic-resistant bacteria [letter]. Emerg Infect Dis [serial
on the Internet]. 2008 Jan [date cited]. Available from http://www.cdc.gov/EID/content/14/1/187.htm
In Response: We appreciate the comments by Dr. Bellissimo-Rodrigues regarding our article analyzing risk factors for surveillance-culture positivity with extended-spectrum β-lactamase (ESBL)–producing bacteria (1). We agree with the author that patient-to-patient transmission is a potentially important causal factor in the emergence of resistance for ESBL-producing bacteria as well as for other antimicrobial drug–resistant bacteria, such as vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and drug-resistant Pseudomonas and Acinetobacter spp. For each of these resistant organisms, a complicated interplay likely exists between the causal importance of antibiotic selective pressure and patient-to-patient transmission by healthcare workers (2–4). The relative importance of these 2 causal mechanisms needs to be determined for each individual antimicrobial-resistant bacterium. The relative causal importance may be different for different outcomes: colonization on admission, colonization acquisition, and progression from colonization to infection. Understanding the relative importance for each of these outcomes is needed before determining whether infection control interventions or antimicrobial drug stewardship policies will be effective. For example, we have published work that demonstrates that patient-to-patient transmission is important for colonization acquisition of ESBL-producing Klebsiella spp. and Escherichia coli (5).
We believe that a couple of points require clarification. In our article, we looked at risk factors for colonization with ESBL-producing bacteria on admission to an intensive care unit. We did not examine risk factors for selecting ESBL-producing bacteria as the letter implies. For the antimicrobial drugs identified as potential risk factors, we clearly stated in the discussion that the risk factors identified may be causally related to the outcome of ESBL-colonization or may only be statistically associated. We argue that even risk factors identified are not causal; they may be important because they can help determine which patients may need empiric antimicrobial drug therapy targeted to the ESBL-producing bacteria. Future research work is still needed to assess the relative importance of patient-to-patient transmission versus antimicrobial selective pressure.
Anthony D. Harris,* Kerri Thom,* and Jessina McGregor†
*University of Maryland, Baltimore, Maryland, USA; and
†Oregon State University, Portland, Oregon, USA
Suggested citation for this article:
Harris AD, Thorn K, McGregor J.
Antimicrobial drug use and antibiotic-resistant bacteria [response]. Emerg
Infect Dis [serial on the Internet]. 2008 Jan [date cited]. Available
from http://www.cdc.gov/EID/content/14/1/187.htm
Please contact the authors at the following addresses:
Fernando Bellissimo-Rodrigues, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto (USP), Av dos Bandeirantes 3900, CEP 14048-900, Ribeirão Preto, SP, Brazil; email: fbellissimo@ig.com.br
Anthony D. Harris, Department of Epidemiology and Preventive Medicine, University of Maryland, 100 N Greene St (lower level), Baltimore, MD 21201, USA; email: aharris@epi.umaryland.edu
Please contact the EID Editors at eideditor@cdc.gov
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
This page posted December 21, 2007
This page last reviewed December 21, 2007
Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, U.S.A
Tel: (404) 639-3311 / Public Inquiries: (404) 639-3534 / (800) 311-3435